Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker.
Nippon Shinyaku Co., Ltd. unveiled a joint research agreement on 4 April with UK-based MiNA Therapeutics Ltd. to develop nucleic acid medicines for an undisclosed rare disease in the central nervous system that the companies described as intractable
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?